Conatus Pharmaceuticals (CNAT) Gains on WSJ Zika-Related Mention
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Conatus Pharmaceuticals (NASDAQ: CNAT) surges following WSJ mention related to Zika. Shares up 15%.
The article discusses liver-disease drug emricasan for use to quell the Zika virus, which Conatus holds several patents on.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioCryst Pharma (BCRX) Shares Ramp to Session Highs Amid Upcoming Galidesivir Data Presentation
- SolarCity (SCTY) October weekly 20 calls active into Tesla (TSLA) reporting Q3 results
- Chipotle (CMG) volatility decreases as shares trade at 52-week low
Create E-mail Alert Related CategoriesFDA, Momentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!